Penumbra reported third-quarter 2026 revenue of $410.1 million, up 15.6% from a year earlier, with growth across its thrombectomy, embolization and access businesses. The medical-device maker also reported a 68.3% gross margin and $229.6 million in operating expenses.
- Thrombectomy revenue rose 18.1% to $279.2 million. U.S. venous thromboembolism (VTE) revenue increased 26.0% year over year.
- Embolization and access revenue grew 10.8% to $131.0 million.
- U.S. neuro revenue increased 19.3% to $77.9 million.
- Gross margin was 68.3%, up 0.5% from the third quarter of 2025, as the company reported it.
- Operating expenses totaled $229.6 million: $25.4 million for research and development and $204.2 million for selling, general and administrative costs. The reported expenses included $7.1 million in costs related to a pending acquisition.
The results show year-over-year revenue growth in each business area reported, with thrombectomy the largest of the listed revenue categories. The available release excerpt does not include net income, earnings per share, cash flow or further details about the pending acquisition.